Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
May 18, 2017
– Phase 3 Programs Underway in Uterine Fibroids and Assisted Reproduction Technology (ART) – Geneva, Switzerland and Boston, MA – May 18, 2017 – ObsEva SA (NASDAQ:…
Read morepress release
– OBE022 is ObsEva’s potential first-in-class, oral and selective PGF2alpha receptor antagonist for the treatment of preterm labor – Geneva, Switzerland and Boston, MA – 18…
Read morepress release
May 16, 2017
Geneva, Switzerland – 16 May 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for…
Read moreJune 29, 2023
May 18, 2022
ObsEva Announces Update on Board of Directors
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 –…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840